European Union - English - EMA (European Medicines Agency)

shionogi b.v. - cefiderocol sulfate tosilate - gram-negative bacterial infections - antibacterials for systemic use, - fetcroja is indicated for the treatment of infections   due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4.2, 4.4 and 5.1).consideration should be given to official guidance on the appropriate use of antibacterial agents.

United States - English - NLM (National Library of Medicine)

shionogi inc. - cefiderocol sulfate tosylate (unii: ttp8lbp45d) (cefiderocol - unii:sz34omg6e8) - fetroja® is indicated in patients 18 years of age or older for the treatment of complicated urinary tract infections (cutis), including pyelonephritis caused by the following susceptible gram-negative microorganisms: escherichia coli , klebsiella pneumoniae , proteus mirabilis , pseudomonas aeruginosa , and enterobacter cloacae complex [see clinical studies (14.1)] . fetroja is indicated in patients 18 years of age or older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible gram-negative microorganisms: acinetobacter baumannii complex, escherichia coli , enterobacter cloacae complex, klebsiella pneumoniae , pseudomonas aeruginosa , and serratia marcescens [see clinical studies (14.2)]. to reduce the development of drug-resistant bacteria and maintain the effectiveness of fetroja and other antibacterial drugs, fetroja should be used only to treat or prevent infections that are proven or strongly suspected to be caus

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

shionogi & co., ltd. - cefiderocol tosilate sulfate hydrate - injection

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil anhydrous 500 mg - cefadroxil capsules, usp are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli, p. mirabilis , and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce the development of drug-resistant bacteria and maintain the effectiveness of

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil anhydrous 500 mg - cefadroxil capsules usp are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli , p. mirabilis , and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce the development of drug-resistant bacteria and maintai

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil anhydrous 500 mg - cefadroxil capsules, usp are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli, p. mirabilis , and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce the development of drug-resistant bacteria and maintain the effectiveness of c

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil anhydrous 500 mg - cefadroxil capsules usp are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli , p. mirabilis , and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce th

United States - English - NLM (National Library of Medicine)

lupin limited - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil anhydrous 500 mg - cefadroxil capsules usp are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli , p. mirabilis , and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce the development of drug-resistant bacteria and maintai

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil anhydrous 250 mg in 5 ml - cefadroxil for oral suspension usp is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli , p. mirabilis , and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce the development of drug-resistant bacteria a

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil anhydrous 500 mg - cefadroxil capsules usp are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli , p. mirabilis , and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce the development of drug-resistant bacteria and maintai